JP2007527407A - 炎症を軽減するためおよび胃腸毒性の処置または予防のための抗炎症性薬学的組成物 - Google Patents

炎症を軽減するためおよび胃腸毒性の処置または予防のための抗炎症性薬学的組成物 Download PDF

Info

Publication number
JP2007527407A
JP2007527407A JP2006533298A JP2006533298A JP2007527407A JP 2007527407 A JP2007527407 A JP 2007527407A JP 2006533298 A JP2006533298 A JP 2006533298A JP 2006533298 A JP2006533298 A JP 2006533298A JP 2007527407 A JP2007527407 A JP 2007527407A
Authority
JP
Japan
Prior art keywords
hops
derived
composition
group
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006533298A
Other languages
English (en)
Japanese (ja)
Inventor
ジョン ジー． バビシュ，
マシュー エル． トリップ，
テレンス ハウエル，
ジェフリー エス． ブランド，
ゲーリー ダーランド，
ロバート ラーマン，
ダニエル オー． ルカツァー，
Original Assignee
メタプロテオミクス， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/464,410 external-priority patent/US8142819B2/en
Priority claimed from US10/464,834 external-priority patent/US20040115290A1/en
Priority claimed from US10/689,856 external-priority patent/US7270835B2/en
Priority claimed from US10/774,048 external-priority patent/US20040219240A1/en
Application filed by メタプロテオミクス， エルエルシー filed Critical メタプロテオミクス， エルエルシー
Publication of JP2007527407A publication Critical patent/JP2007527407A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006533298A 2003-05-22 2004-05-21 炎症を軽減するためおよび胃腸毒性の処置または予防のための抗炎症性薬学的組成物 Pending JP2007527407A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US47246003P 2003-05-22 2003-05-22
US10/464,410 US8142819B2 (en) 2002-10-21 2003-06-18 Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US10/464,834 US20040115290A1 (en) 2001-06-20 2003-06-18 Modulation of inflammation by hops fractions and derivatives
US10/689,856 US7270835B2 (en) 2001-06-20 2003-10-20 Compositions that treat or inhibit pathological conditions associated with inflammatory response
US10/774,048 US20040219240A1 (en) 2001-06-20 2004-02-05 Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
PCT/US2004/016043 WO2005039483A2 (en) 2003-05-22 2004-05-21 Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011071217A Division JP2011126919A (ja) 2003-05-22 2011-03-28 炎症を軽減するためおよび胃腸毒性の処置または予防のための抗炎症性薬学的組成物

Publications (1)

Publication Number Publication Date
JP2007527407A true JP2007527407A (ja) 2007-09-27

Family

ID=44303194

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006533298A Pending JP2007527407A (ja) 2003-05-22 2004-05-21 炎症を軽減するためおよび胃腸毒性の処置または予防のための抗炎症性薬学的組成物
JP2011071217A Withdrawn JP2011126919A (ja) 2003-05-22 2011-03-28 炎症を軽減するためおよび胃腸毒性の処置または予防のための抗炎症性薬学的組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011071217A Withdrawn JP2011126919A (ja) 2003-05-22 2011-03-28 炎症を軽減するためおよび胃腸毒性の処置または予防のための抗炎症性薬学的組成物

Country Status (11)

Country Link
US (1) US7811610B2 (US20070202208A1-20070830-C00006.png)
EP (1) EP1626731B1 (US20070202208A1-20070830-C00006.png)
JP (2) JP2007527407A (US20070202208A1-20070830-C00006.png)
KR (1) KR20060105429A (US20070202208A1-20070830-C00006.png)
AT (1) ATE421357T1 (US20070202208A1-20070830-C00006.png)
AU (2) AU2004283065B2 (US20070202208A1-20070830-C00006.png)
CA (1) CA2526804A1 (US20070202208A1-20070830-C00006.png)
ES (1) ES2323708T3 (US20070202208A1-20070830-C00006.png)
MX (1) MXPA05012584A (US20070202208A1-20070830-C00006.png)
NZ (1) NZ543726A (US20070202208A1-20070830-C00006.png)
WO (1) WO2005039483A2 (US20070202208A1-20070830-C00006.png)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525523A (ja) * 2004-02-27 2007-09-06 メタプロテオミクス， エルエルシー クルクミノイドまたはメチルキサンチンを用いての相乗的な抗炎症医薬組成物および関連する方法
JP2012025719A (ja) * 2010-07-28 2012-02-09 Morinaga Milk Ind Co Ltd プロトンポンプ阻害剤
JP2013177369A (ja) * 2012-01-30 2013-09-09 Lion Corp 一酸化窒素産生抑制剤
JP2021102612A (ja) * 2014-12-24 2021-07-15 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗α４β７インテグリン抗体による治療の結果の予測

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168234B2 (en) 2001-06-20 2012-05-01 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US8158160B2 (en) 2001-11-13 2012-04-17 Eric Hauser Kuhrts Anti-inflammatory cyclooxygenase inhibitors
BRPI0901298A2 (pt) 2009-04-06 2011-01-04 Ems Sa derivados ftalimìdicos de compostos antiinflamatórios não-esteróide e/ou moduladores de tnf-(alfa), processo de sua obtenção, composições farmacêuticas contendo os mesmos e seus usos no tratamento de doenças inflamatórias
AU2011320140C1 (en) 2010-10-30 2019-12-12 Kindex Pharmaceuticals, Inc. Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(-3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods
CN108096283B (zh) * 2017-12-29 2020-08-07 广西壮族自治区中医药研究院 拟黑多刺蚁提取物作为制备防治瘙痒药物的用途
CN110680819A (zh) * 2018-07-06 2020-01-14 云南民族大学 一种三萜皂苷类化合物的应用
CN111458490B (zh) * 2020-03-18 2023-06-27 广州市华永睿健生物科技有限公司 长寿家族的肠道代谢图谱的建立及其在增龄健康领域的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002505296A (ja) * 1998-03-04 2002-02-19 エヌピーエス ファーマシューティカルズ インコーポレーテッド Ｎｓａｉｄとともにカノコソウ抽出物、イソ吉草酸またはその誘導体を含む組成物
WO2003000185A2 (en) * 2001-06-20 2003-01-03 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
WO2003035007A2 (en) * 2001-10-26 2003-05-01 Metaproteomics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933919A (en) 1964-12-15 1976-01-20 Geoffrey Wilkinson Hydroformylation of mono-α-olefins and mono-α-acetylenes
GB1140545A (en) 1965-03-01 1969-01-22 Kalamazoo Spice Extract Co Hop flavours for malt beverages and the like
US3451821A (en) 1965-03-01 1969-06-24 Kalamazoo Spice Extract Co Increasing the utilization of hops and improving flavor control of malt beverages and the like
US3720517A (en) 1970-12-21 1973-03-13 Hamm T Brewing Co Preparation of a fermented malt champagne
US3932603A (en) 1971-05-28 1976-01-13 General Foods Corporation Oral preparations for reducing the incidence of dental caries
GB1372932A (en) 1971-03-15 1974-11-06 Gen Foods Corp Anti-caries compositions
US3965188A (en) 1972-01-10 1976-06-22 Miller Brewing Company Hop extract process and product
CH617326A5 (US20070202208A1-20070830-C00006.png) 1975-12-04 1980-05-30 Siegfried Ag
US4148873A (en) 1976-11-05 1979-04-10 S. S. Steiner, Inc. Method for treating the skin with extracts of hops
US4170638A (en) 1976-11-05 1979-10-09 S. S. Steiner, Inc. Method for producing a deodorant
US4123561A (en) 1977-02-01 1978-10-31 S.S. Steiner, Inc. Method for processing hops for brewing
US4401684A (en) 1981-10-01 1983-08-30 Australian Hop Marketers Pty. Ltd. Preservation of hops utilizing ascorbic acid
US4389421A (en) 1981-10-30 1983-06-21 Busch Industrial Products Corporation Method for controlling light stability in malt beverages and product thereof
BE896610A (fr) 1982-05-06 1983-08-16 Hop Developments Ltd Extraction d'une matiere vegetale en utilisant de l'anhydride carbonique
US4473551A (en) 1982-08-23 1984-09-25 Faxon Pharmaceuticals, Inc. Anti-inflammatory composition
US4644084A (en) 1984-01-25 1987-02-17 Miller Brewing Company Preparation of tetrahydroisohumulones
GB2187755B (en) 1984-02-28 1990-03-28 Kalamazoo Holdings Inc Separation of the constituents of co2 hop extracts
SU1247011A1 (ru) 1985-02-20 1986-07-30 Специальное Конструкторское Бюро Химизации Научно-Производственного Объединения "Аэрозоль" Средство дл ухода за волосами
US4767640A (en) 1985-10-29 1988-08-30 Miller Brewing Company Light stable hop extracts and method of preparation
US4692280A (en) 1986-12-01 1987-09-08 The United States Of America As Represented By The Secretary Of Commerce Purification of fish oils
US5041300A (en) 1987-04-03 1991-08-20 Kalamazoo Holdings, Inc. Hop flavor which is odor forming impurity free
DE3712986A1 (de) 1987-04-16 1988-10-27 Marbert Gmbh Medizinische zubereitungen auf der grundlage von biertreberextrakt, verfahren zu deren herstellung sowie verwendung von biertreberextrakt zur herstellung von kosmetischen zubereitungen und ein spezieller biertreberextrakt
US4857554A (en) 1987-08-17 1989-08-15 Georgios Kallimanis Method for the treatment of psoriasis
US5166449A (en) 1988-08-15 1992-11-24 Kalamazoo Holdings, Inc. Synthesis of hexahydrolupulone, novel forms thereof, and its use as a selective inhibitor of cell growth and multiplication
US5082975A (en) 1988-08-15 1992-01-21 Kalamazoo Holdings, Inc. Synthesis of hexahydrolupulone, novel forms thereof, and its use as a selective inhibitor of cell growth and multiplication
DE3931147A1 (de) 1989-09-19 1991-03-28 Solong Natural Ltd Nerventonikum fuer frauen zum abbau psychisch bedingter sterilitaet
US5013571A (en) 1990-01-31 1991-05-07 Pfizer Inc. Methods for making tetrahydroisoalpha and hexahydroisoalpha acids
DE59010282D1 (de) 1990-09-10 1996-05-15 Fromm Mayer Bass Ltd Verfahren zur Isomerisierung von Humulon in einem Kohlendioxid-Hopfenextrakt und ein Verfahren zur Gewinnung von Isohumulon daraus
JP3155003B2 (ja) 1990-11-06 2001-04-09 サントリー株式会社 ホップエキスの製造法および該方法により得られるホップエキス
TW199905B (en) 1992-02-03 1993-02-11 J E Siebel Sons Company Inc Method and composition for enhancing foam properties of fermented malt beverages
RU2045955C1 (ru) 1992-02-24 1995-10-20 Никитина Татьяна Ивановна Способ лечения аднекситов
ATE188609T1 (de) 1992-07-29 2000-01-15 Drymed A S Befruchtete muscheleier enthaltende zusammensetzung
US5286506A (en) 1992-10-29 1994-02-15 Bio-Technical Resources Inhibition of food pathogens by hop acids
US5370863A (en) 1992-12-16 1994-12-06 Miller Brewing Company Oral care compositions containing hop acids and method
US5296637A (en) * 1992-12-31 1994-03-22 Kalamazoo Holdings, Inc. Production of odor-free tetrahydroisohumulates from alpha acids via their tetrahydrohumulates and subsequent isomerization
US5866162A (en) * 1993-08-10 1999-02-02 Smithkline Beecham P.L.C. Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple
JP2677762B2 (ja) * 1994-04-08 1997-11-17 株式会社神戸製鋼所 油冷式圧縮機
DE69507185T2 (de) 1994-04-12 1999-09-09 Hoechst Marion Roussel Inc Arzneimittel zur Behandlung von Osteoporose
AT404469B (de) 1994-05-06 1998-11-25 Tulln Zuckerforschung Gmbh Verfahren zur konservierung von zuckerhaltigen pflanzenextrakten- bzw. säften
IN184685B (US20070202208A1-20070830-C00006.png) 1996-02-14 2000-09-23 Nat Inst Immunology
US5827895A (en) 1996-02-27 1998-10-27 Regents Of The University Of Minnesota Hexahydrolupulones useful as anticancer agents
US6020019A (en) 1996-03-26 2000-02-01 Miller Brewing Company Hydrogenation of hop soft resins using CO2
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US5968539A (en) 1997-06-04 1999-10-19 Procter & Gamble Company Mild, rinse-off antimicrobial liquid cleansing compositions which provide residual benefit versus gram negative bacteria
US6021243A (en) 1997-10-06 2000-02-01 Nec Research Institute, Inc. Low-cost planar star-coupling structure for large-core polymer optical fibers
US6251461B1 (en) 1997-10-10 2001-06-26 S. S. Steiner, Inc. Antimicrobial activity of hops extract against Clostridium botulinum, Clostridium difficile and Helicobacter pylori
US5919813C1 (en) 1998-03-13 2002-01-29 Univ Johns Hopkins Med Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
CN1203268A (zh) 1998-05-18 1998-12-30 莫程鹏 绞股蓝啤酒制造方法
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
DE19841615A1 (de) 1998-09-11 2000-03-16 Fritz Armin Mueller Weinfemina
ES2147538B1 (es) 1999-01-29 2001-04-01 Revlon Consumer Prod Corp Una locion capilar con propiedades mejoradas en su accion protectora del cabello y preventiva de su caida, y de reduccion de los efectos externos de la alopecia androgenetica y con ello de la caida del cabello.
ZA200000857B (en) 1999-02-11 2001-05-31 Marx Anna Susan Pharmaceutical composition.
US6801860B1 (en) 1999-02-15 2004-10-05 Genetics Institute, Llc Crystal structure of cPLA2 and methods of identifying agonists and antagonists using same
US6383527B1 (en) 1999-03-04 2002-05-07 Nps Pharmaceuticals, Inc. Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID
JP4173606B2 (ja) 1999-06-18 2008-10-29 サントリー株式会社 低酸性飲料の製造方法
US6129907A (en) 1999-08-04 2000-10-10 Colgate Palmolive Company Stable hydrogenated lupulone antibacterial oral compositions
DE19939350B4 (de) 1999-08-19 2005-04-07 Plantextrakt Gmbh & Co. Kg Hopfenextrakt und Verfahren zu dessen Herstellung
WO2001021165A1 (en) 1999-09-21 2001-03-29 Rutgers, The State University Resveratrol analogs for prevention of disease
US6200594B1 (en) 1999-12-29 2001-03-13 Vital Dynamics, Inc. Breast-enhancing, herbal compositions and methods of using same
US6953593B2 (en) 2000-02-01 2005-10-11 Lipoprotein Technologies, Inc. Sustained-release microencapsulated delivery system
US6583322B1 (en) 2000-02-25 2003-06-24 Kalamazoo Holdings, Inc. Dihydro and hexahydro isoalpha acids having a high ratio of trans to cis isomers, production thereof, and products containing the same
US20020086070A1 (en) 2000-03-11 2002-07-04 Kuhrts Eric Hauser Anti-inflammatory and connective tissue repair formulations
JP3958968B2 (ja) 2000-03-31 2007-08-15 日清オイリオグループ株式会社 皮膚外用剤及び美白剤
US6440465B1 (en) 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
US6908630B2 (en) 2000-08-01 2005-06-21 Metaproteomics, Llc Combinations of sesquiterpene lactones and ditepene triepoxide lactones for synergistic inhibition of cyclooxygenase-2
US20020076452A1 (en) 2000-08-01 2002-06-20 Ashni Naturaceuticals, Inc. Combinations of sesquiterpene lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2
FR2815227B1 (fr) 2000-10-17 2003-04-11 Schwartz Laboratoires Robert Composition anti-stress destinee a etre incorporee principalement a des vehicules nutritionnels
US6790459B1 (en) 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
CA2435522C (en) 2001-01-31 2010-02-23 Rex Medical, L.P. Apparatus for stapling and resectioning gastro-esophageal tissue
US6391346B1 (en) 2001-04-05 2002-05-21 Thomas Newmark Anti-inflammatory, sleep-promoting herbal composition and method of use
US20030003212A1 (en) 2001-06-13 2003-01-02 Givaudan Sa Taste modifiers
US20040115290A1 (en) 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US7901714B2 (en) 2001-06-20 2011-03-08 Metaproteomics, Llp Treatment modalities for autoimmune diseases
US20040219240A1 (en) 2001-06-20 2004-11-04 Babish John G. Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
US7718198B2 (en) 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
US7901713B2 (en) 2001-06-20 2011-03-08 Metaproteomics, Llc Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
US8168234B2 (en) 2001-06-20 2012-05-01 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7270835B2 (en) 2001-06-20 2007-09-18 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US8142819B2 (en) 2002-10-21 2012-03-27 Metaproteomics, Llc Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US7279185B2 (en) 2001-10-26 2007-10-09 Metaproteonics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US7108868B2 (en) 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
US20050147698A1 (en) 2002-03-28 2005-07-07 Alcon, Inc. Co-beadlet of dha and rosemary and methods of use
US20030228369A1 (en) 2002-05-06 2003-12-11 Kuhrts Eric Hauser Process for conversion of high viscosity fluids and compositions thereof
WO2004037180A2 (en) 2002-10-21 2004-05-06 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7144590B2 (en) 2003-01-09 2006-12-05 Lipoprotein Technologies, Inc. Bioactive compositions derived from humulus lupulus
US20050192356A1 (en) 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002505296A (ja) * 1998-03-04 2002-02-19 エヌピーエス ファーマシューティカルズ インコーポレーテッド Ｎｓａｉｄとともにカノコソウ抽出物、イソ吉草酸またはその誘導体を含む組成物
WO2003000185A2 (en) * 2001-06-20 2003-01-03 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
WO2003035007A2 (en) * 2001-10-26 2003-05-01 Metaproteomics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525523A (ja) * 2004-02-27 2007-09-06 メタプロテオミクス， エルエルシー クルクミノイドまたはメチルキサンチンを用いての相乗的な抗炎症医薬組成物および関連する方法
JP2012025719A (ja) * 2010-07-28 2012-02-09 Morinaga Milk Ind Co Ltd プロトンポンプ阻害剤
JP2013177369A (ja) * 2012-01-30 2013-09-09 Lion Corp 一酸化窒素産生抑制剤
JP2021102612A (ja) * 2014-12-24 2021-07-15 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗α４β７インテグリン抗体による治療の結果の予測

Also Published As

Publication number Publication date
JP2011126919A (ja) 2011-06-30
KR20060105429A (ko) 2006-10-11
ATE421357T1 (de) 2009-02-15
CA2526804A1 (en) 2005-05-06
EP1626731A4 (en) 2006-08-02
NZ543726A (en) 2009-08-28
WO2005039483A3 (en) 2005-09-29
AU2010200710A1 (en) 2010-03-18
US20070202208A1 (en) 2007-08-30
MXPA05012584A (es) 2006-05-25
EP1626731A2 (en) 2006-02-22
AU2004283065B2 (en) 2009-11-26
US7811610B2 (en) 2010-10-12
EP1626731B1 (en) 2009-01-21
AU2004283065A1 (en) 2005-05-06
WO2005039483A2 (en) 2005-05-06
ES2323708T3 (es) 2009-07-23

Similar Documents

Publication Publication Date Title
JP2011126919A (ja) 炎症を軽減するためおよび胃腸毒性の処置または予防のための抗炎症性薬学的組成物
US20040219240A1 (en) Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
JP4860600B2 (ja) 相乗的な抗炎症医薬組成物および使用方法
AU2003286549C1 (en) Compositions that treat or inhibit pathological conditions associated with inflammatory response
EP2221052A2 (en) Compositions that treat or inhibit pathological conditions associated with inflammatory response
JP2007525523A (ja) クルクミノイドまたはメチルキサンチンを用いての相乗的な抗炎症医薬組成物および関連する方法
JP2011093918A (ja) シクロオキシゲナーゼ−２の発現および／または活性の相乗的阻害を示すクルクミノイド組成物
US7807203B2 (en) Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
KR20070018046A (ko) 커큐미노이드 또는 메틸크산틴을 이용한 상승작용성항염증성 약학적 조성물 및 관련된 방법

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100928

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101229

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110106

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110930

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120402